Home » Newsletters » BioWorld Science

BioWorld Science

June 5, 1997

View Archived Issues

SANG-35 bioequivalent to Neoral in healthy volunteers

Preclinical and preliminary clinical data on anseculin reported

Merz glycineB antagonists characterized

In vitro anti-HIV activity of FddA

Novel antiparkinsonian agent in development at Kyowa Hakko

New use for ondansetron tested in clinical trials

Focus on drug interactions with a common food: grapefruit

5-LO inhibitor improves transplant preservation injury

Cholesterol-lowering activity of squalene synthase inhibitor in animal models

Efficacy of chronic treatment with tolcapone + levodopa in Parkinson's disease

Bristol-Myers Squibb expands protease inhibitor research

Noven reports clinical trial results with transoral delivery system

Didronel PMO approved for prevention of osteoporosis in U.K.

Oculex and Storz sign marketing agreement for ocular product

Axcan acquires U.S. rights to Viokase

3M to launch Aldara next week

First launch for lepirudin

Launch of Microscience, a microbiology company focused on infectious diseases

In vitro activity of MEN-10700 assessed

Diatide's P829 reliably excludes malignancy in patients with SPN

PRIZM and Chiron begin gene therapy collaboration

Penederm receives SBIR grant for research on vitamin D derivative

Techniclone finalizes acquisition of Peregrine

U.S. patent covers use of Synsorb Cd in C. difficile-associated diarrhea

Pfizer sponsors Canadian study of drug treatment in later stages of AD

Organon team identifies rheumatoid arthritis-related antigen

Transgenic mouse model of AD developed by Canadian researchers

ProScript milestone in inflammatory disease/cancer collaboration triggers payment from HMR

Millennium issued U.S. patent for melanoma gene

Antiamnesic effects of RU-47231 in rats

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...